ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Anesthetic effects on electrophysiological responses across the visual pathway.Scientific reports · 2024Article
- Stem cell therapy in retinal diseases.Neural regeneration research · 2023Review
- Peptide cargo administration: current state and applications.Applied microbiology and biotechnology · 2023Review
- Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.Asian journal of pharmaceutical sciences · 2022Review
- Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art.Frontiers in medicine · 2021Review
- Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.Molecules (Basel, Switzerland) · 2019Review
- Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide.Molecular therapy. Nucleic acids · 2019Article
- Bacterial magnetic particles improve testes-mediated transgene efficiency in mice.Drug delivery · 2017Article
- Reducible PEG-POD/DNA Nanoparticles for Gene Transfer In Vitro and In Vivo: Application in a Mouse Model of Age-Related Macular Degeneration.Molecular therapy. Nucleic acids · 2017Article
- Nanotechnology-based strategies for treatment of ocular disease.Acta pharmaceutica Sinica. B · 2017Review
- Corneal Penetrating Elastin-Like Polypeptide Carriers.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016Article
- G-quartet oligonucleotide mediated delivery of proteins into photoreceptors and retinal pigment epithelium via intravitreal injection.Experimental eye research · 2016Article
- Article
- Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery.International journal of nanomedicine · 2015Article
- Vector platforms for gene therapy of inherited retinopathies.Progress in retinal and eye research · 2014Review
- Genetically modified neural stem cells for a local and sustained delivery of neuroprotective factors to the dystrophic mouse retina.Stem cells translational medicine · 2013Article
- Extended duration of transgene expression from pegylated POD nanoparticles enables attenuation of photoreceptor degeneration.PloS one · 2013Article
- Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose.Gene therapy · 2012Article
- Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame?The Journal of biological chemistry · 2012Review
- Adaptive Müller cell responses to microglial activation mediate neuroprotection and coordinate inflammation in the retina.Journal of neuroinflammation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Peptide for ocular delivery (POD) is a novel cationic cell-penetrating peptide (CPP) which, when conjugated with polyethylene glycol (PEG-POD), can deliver plasmid DNA to the retinal pigment epithelium (RPE) of adult murine retina. PEG-POD nanoparticles containing an expression cassette for glial cell line-derived neurotrophic factor (PEG-POD~GDNF) were investigated for their ability to inhibit light-induced photoreceptor apoptosis. PEG-POD~GDNF, control nanoparticles, or buffer were injected into the subretinal space of adult murine retina and retinal degeneration induced by blue light. Animals injected with PEG-POD~GDNF showed a significant reduction (3.9-7.7 fold) in apoptosis relative to control-injected animals. The thickness of the outer nuclear layer (ONL) of the superior retina of PEG-POD~GDNF-injected eyes was significantly greater (23.6-39.3%) than control-injected retina 14 days post-light treatment. PEG-POD~GDNF-injected eyes showed a 27-39% greater functional response relative to controls, as measured by electroretinogram (ERG) 7 days post-light treatment. This is one of only two studies demonstrating histological and functional rescue of a mouse model of retinal degeneration following nonviral administration of a transgene into adult retina. Although rescue is short lived for clinical application, this study represents an important step in the development of nonviral gene therapy for retinal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.